Teduglutide from Creative Peptides Helps You Gain Further Success in SBS Research
Shirley, NY, March 30, 2016 -- Creative Peptides, a reliable supplier of peptides manufacturing upon academic, clinical, commercial and government laboratories in diverse applications, is concentrated on developing its effective product - Teduglutide.
Teduglutide, also known as Gattex/ALX 0600, is mainly used for the treatment of short bowel syndrome (SBS). The disease is generally due to a series of syndromes caused by a serious intestinal disease or the surgical removal of most small intestines. People with SBS cannot absorb enough water, vitamins, and other nutrients from food to sustain life. The treatment options are complex and varied as well. Clinical trials have shown that the teduglutide is capable of reducing certain demands of short bowel syndrome patients towards parenteral nutrition, which is currently the first non-surgical treatment for SBS.
In particular, teduglutide, as the glucagon-like peptide-2 (GLP-2) analogue, is a protein related to gut’s growth and functions. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion and can be used as the targeted therapy in SBS. In addition to the existing cumbersome intravenous administration with parenteral nutrition, teduglutide can also be another choice for mass researchers.
Based on the fact, Creative Peptides has tried to discover more effective methods for meeting the increasing demands from a full range of scientific groups. Specifically, its teduglutide is indicated for the treatment of intestinal failure associated with SBS, which can help the researchers gain more information about peptide secreted primarily in the distal intestine and involved in the regeneration and repair of the intestinal epithelium, such as Acetyl octapeptide-1. In this way, researchers can perform better in the analysis and handling of the databases. With the technical assistance from Creative Peptides, a better understanding upon clinical efficacy of teduglutide in SBS can be enabled.
Clearly, teduglutide has displayed intestinotrophic properties in humans, possibly as a result of increasing the absorptive surface area of intestine. More detailed information can be learned on the website of Creative Peptides.
About Creative Peptides
Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. It provides customers with manufacturing services to the peptide manufacturers for the biopharmaceutical market.
Contact:
Creative Peptides
45-16 Ramsey Road
Shirley, NY 11967, USA
Tel: 16316244882
Fax: 16316147828
contact@creative-peptides.com
http://www.creative-peptides.com